CHARM Renal Subgroup Score: Explanation and Clinical Context The CHARM Renal Subgroup Score was developed from the CHARM trials to assess prognosis in heart failure patients with renal dysfunction.
It incorporates age, renal function (serum creatinine), NYHA class, and comorbidities such as diabetes, hypertension, and prior myocardial infarction.
Higher scores are associated with increased risk of cardiovascular death or heart failure hospitalization.
This tool helps clinicians stratify risk and guide management intensity in patients with heart failure and renal impairment.
Reference:
Pfeffer MA, et al. "Effects of Candesartan on Mortality and Morbidity in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction With and Without Renal Dysfunction: The CHARM Program." N Engl J Med. 2003;349:1893-1906. doi:10.1056/NEJMoa035260